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Background-—Impaired microcirculatory reperfusion worsens prognosis following acute ST-segment–elevation myocardial
infarction. In the T-TIME (A Trial of Low-Dose Adjunctive Alteplase During Primary PCI) trial, microvascular obstruction on
cardiovascular magnetic resonance imaging did not differ with adjunctive, low-dose, intracoronary alteplase (10 or 20 mg) versus
placebo during primary percutaneous coronary intervention. We evaluated the effects of intracoronary alteplase, during primary
percutaneous coronary intervention, on the index of microcirculatory resistance, coronary ﬂow reserve, and resistive reserve ratio.
Methods and Results-—A prespeciﬁed physiology substudy of the T-TIME trial. From 2016 to 2017, patients with ST-segment–
elevation myocardial infarction ≤6 hours from symptom onset were randomized in a double-blind study to receive alteplase 20 mg,
alteplase 10 mg, or placebo infused into the culprit artery postreperfusion, but prestenting. Index of microcirculatory resistance,
coronary ﬂow reserve, and resistive reserve ratio were measured after percutaneous coronary intervention. Cardiovascular
magnetic resonance was performed at 2 to 7 days and 3 months. Analyses in relation to ischemic time (<2, 2–4, and ≥4 hours)
were prespeciﬁed. One hundred forty-four patients (mean age, 5911 years; 80% male) were prospectively enrolled, representing
33% of the overall population (n=440). Overall, index of microcirculatory resistance (median, 29.5; interquartile range, 17.0–55.0),
coronary ﬂow reserve(1.4 [1.1–2.0]), and resistive reserve ratio (1.7 [1.3–2.3]) at the end of percutaneous coronary intervention
did not differ between treatment groups. Interactions were observed between ischemic time and alteplase for coronary ﬂow
reserve (P=0.013), resistive reserve ratio (P=0.026), and microvascular obstruction (P=0.022), but not index of microcirculatory
resistance.
Conclusions-—In ST-segment–elevation myocardial infarction with ischemic time ≤6 hours, there was overall no difference in
microvascular function with alteplase versus placebo.
Clinical Trial Registration-—URL: https://www.clinicaltrials.gov. Unique identiﬁer: NCT02257294. ( J Am Heart Assoc. 2020;9:
e014066. DOI: 10.1161/JAHA.119.014066.)
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F ailed myocardial reperfusion affects approximately half ofpatients with acute ST-segment–elevation myocardial
infarction (STEMI) following primary percutaneous coronary
intervention (PCI),1 and microvascular obstruction confers a
worse prognosis.2–4 Microvascular obstruction is an acute,
but potentially reversible, pathology. The pathophysiology
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includes microvascular thrombi, endothelial disruption, and, if
reperfusion does not occur, then irreversible hemorrhagic
transformation occurs within the infarct core.5
Facilitated PCI with full- or half-dose ﬁbrinolytic therapy
given intravenously pre-PCI improves initial coronary ﬂow, but
promotes paradoxical thrombus formation, which counteracts
ﬁbrinolysis and is associated with higher residual thrombus
burden, thrombotic complications, bleeding, and mortality.6–8
In the T-TIME (A Trial of Low-Dose Adjunctive Alteplase During
Primary PCI) trial (NCT02257294), we hypothesized that low-
dose, intracoronary ﬁbrinolysis with adequate anticoagulation
would reduce intracoronary and microvascular thrombosis
and distal embolization without activating thrombus forma-
tion, thereby reducing microvascular obstruction. However, as
assessed by contrast-enhanced cardiovascular magnetic
resonance (CMR) imaging, microvascular obstruction did not
differ with low-dose intracoronary alteplase versus placebo.9
In contrast with CMR, the index of microcirculatory
resistance (IMR) quantiﬁes immediate efﬁcacy of microcircu-
latory reperfusion.10,11 Elevated IMR is quantitatively associ-
ated with microvascular obstruction,12,13 myocardial
hemorrhage,12 worse recovery of infarct size,14 and adverse
left ventricular (LV) remodeling and function.15 In acute
STEMI, an IMR ≤32 post-PCI predicts recovery of LV
function16 whereas an IMR ≥32 predicts all-cause death or
rehospitalization for heart failure.13 An IMR >40 after primary
PCI has been associated with all-cause death, heart failure
readmissions, and major adverse cardiac events.13–15
Resistive reserve ratio (RRR) measures the vasodilatory
capacity of the coronary microcirculation. It is the ratio
between basal resting tone and resistance at maximal
hyperemia and is lower when microvasodilatation is impaired.
Coronary ﬂow reserve (CFR) reﬂects epicardial and microcir-
culatory vasodilator capacity, as well as residual epicardial
stenosis. CFR is the ratio of hyperemic to resting coronary
blood ﬂow. In acute STEMI, a lower RRR and CFR predict
microvascular obstruction12,17 and larger infarction.17,18
We prospectively investigated the effects of intracoronary
alteplase during primary PCI on acute invasive parameters of
microcirculatory function. We hypothesized that intracoronary
alteplase would be associated with lower IMR, higher CFR,
and higher RRR. Second, we hypothesized that the effects of
alteplase on IMR, CFR, and RRR may vary with ischemic time,
TIMI (Thrombolysis in Myocardial Infarction) thrombus grade,
and TIMI coronary ﬂow grade at the time of drug delivery
(prespeciﬁed interaction analyses).
Methods
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.
Study Design and Patient Selection
We performed a predeﬁned, prospective, nested substudy
within the main T-TIME trial. From August 2016 to December
2017, patients with acute STEMI from 3 hospitals in the
United Kingdom were randomized in a 1:1:1 dose-ranging,
double-blind study. The protocol is summarized in Figure 1.
Participants were treated according to contemporary practice
guideline recommendations.4
Patients were eligible for study participation if they
presented with persistent ST-segment elevation or recent left
bundle branch block within 6 hours of symptom onset and
either an occluded culprit artery (TIMI coronary ﬂow grade ≤1)
or reduced ﬂow (TIMI ﬂow grade 2, slow but complete ﬁlling) in
the presence of angiographic evidence of thrombus (TIMI
thrombus grade ≥2). Eligibility required radial artery access,
and the occlusion had to be in the proximal or mid segment of a
major coronary artery. Exclusion criteria included a functional
coronary collateral supply (Rentrop grade ≥2) to the culprit
artery, cardiogenic shock, comorbidities with expected survival
<1 year and contraindications to ﬁbrinolysis, or CMR. The full
list of eligibility criteria is provided in Data S1.
Enrollment into the physiology study within the 3 desig-
nated sites was based on prospective assessment of eligibility
criteria, operator experience, and logistical considerations at
the point of care. A screening register was prospectively
completed to document the reasons for participation or not.
Witnessed verbal assent to participate in the study was
obtained in the catheterization laboratory, and written
informed consent was subsequently obtained on the ward.
Clinical Perspective
What Is New?
• Overall, there was no difference in index of microcirculatory
resistance, coronary ﬂow reserve, or resistive reserve ratio
with alteplase versus placebo.
• Patients presenting with a limited ischemic time (<2 hours)
had dose-related improvements in microvascular function
(coronary ﬂow reserve and resistive reserve ratio) with
alteplase versus placebo.
• Patients presenting with longer ischemic times (≥4 hours)
had increased microvascular obstruction extent with
alteplase versus placebo.
What Are the Clinical Implications?
• The ﬁndings are relevant to ongoing trials of intracoronary
ﬁbrinolytics during primary percutaneous coronary interven-
tion, and to clinicians considering bail-out lytic therapy in
acute ST-segment–elevation myocardial infarction patients,
with high thrombus burden and no reﬂow.
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Figure 1. Illustration of the study design. Acute STEMI patients meeting the eligibility criteria were enrolled in the catheterization
laboratory and randomized to placebo, alteplase 10 mg, or alteplase 20 mg, in a 1:1:1 dose-ranging, double-blind design. CFR indicates
coronary ﬂow reserve; IMH, intramyocardial hemorrhage; IMR, index of microcirculatory resistance; MVO, microvascular obstruction; PCI,
percutaneous coronary intervention; RRR, resistive reserve ratio; STEMI, ST-segment–elevation myocardial infarction.
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The study complied with the Declaration of Helsinki19 and was
approved by the West of Scotland Research Ethics Committee
(reference 13-WS-0119).
Randomization and Intervention
Patients were randomized using an interactive voice-
response–based system. The randomization sequence was
computer generated, using the method of randomized
permuted blocks of length 6, with stratiﬁcation by location
of STEMI (anterior versus nonanterior). The allocation
sequence was on a 1:1:1 basis between placebo and the
reduced dose alteplase groups (10, 20 mg; ie, one-tenth or
one-ﬁfth of the standard dose). Patients, staff, and research-
ers were blinded to treatment group allocation.
After successful reperfusion (TIMI ﬂow grade ≥2) was
achieved, using balloon angioplasty and/or aspiration
thrombectomy, patients received the allocated intervention
immediately in the catheterization laboratory. The 20-mL
volume of study drug was manually infused into the culprit
coronary artery over 5 to 10 minutes proximal to the culprit
lesion, using either an intracoronary catheter or the guiding
catheter if selectively engaged.
Intracoronary Physiology Measurements and
Analysis
IMR, CFR, and RRR were measured at the end of primary PCI,
using a pressure- and temperature-sensing guidewire (Abbott
Vascular, Santa Clara, CA). All patients received 200 lg of
intracoronary nitroglycerin in the culprit artery. The calibrated
wire was equalized to guide catheter pressure, then advanced
to the distal third of the culprit artery. Using standard
thermodilution methodology, mean transit time (Tmn) of a
hand-injected 3-mL bolus of room-temperature saline was
measured in triplicate at rest and during steady-state maximal
hyperemia induced by intravenous adenosine (140 lg/kg/
min). In order to mitigate the possibility of bias through
disclosure of the IMR, CFR, and RRR results, the operators
were blinded. The blinding process involved obscuring the
display of the RadiAnalyzer Xpress monitor by turning it away
from the clinician and other clinical staff. Experienced
physiology technicians recorded the thermodilution data and
quality assured the acquisition.
IMR was quantiﬁed by distal coronary pressure 9 Tmn
during hyperemia.20 At the end of primary PCI when IMR was
measured after stenting, there was no residual epicardial
stenosis, and therefore IMR correction with coronary wedge
pressure21 or Yong’s formula22 was not required. CFR was
quantiﬁed by dividing resting Tmn by hyperemic Tmn.23,24
RRR was quantiﬁed by dividing the baseline resistance index
(distal coronary pressure 9 Tmn under resting conditions) by
IMR.25 The shape of the hyperemic thermodilution curves was
assessed as narrow unimodal, wide unimodal, or bimodal.26 A
narrow unimodal waveform was deﬁned as an acute temper-
ature reduction (duration of <0.42 seconds from the begin-
ning of the temperature reduction to nadir temperature),
followed by rapid return to resting temperature. A wide
unimodal waveform was deﬁned as a temperature decrease to
nadir >0.42 seconds, followed by a gradual return to baseline
temperature. A bimodal waveform was deﬁned as having 2
distinct nadirs, with a valley deeper than 20% of peak
temperature drop.
All data were extracted from the RadiAnalyzer Xpress
instrument and then analyzed ofﬂine using Coroﬂow software
(Coroventis Research AB, Uppsala, Sweden) by an investigator
blinded to treatment allocation and blinded to CMR data. The
coronary physiology data were subject to a second read, and
ﬁnal data were established by consensus agreement.
Angiographic, ECG, and Troponin Analyses
ECG and angiographic end points were determined by blinded
core laboratory analysis, using standard operating procedures.
Angiograms were analyzed by A.M.M. and then subject to a
second read by 1 of 2 interventional cardiologists, both with
>10 years of experience. Discrepancies were resolved by
consensus agreement between the ﬁrst and second review-
ers, or where discrepancies remained consensus was reached
after discussion with a third reviewer. The following were
assessed in the culprit artery: TIMI coronary ﬂow grade, TIMI
frame count, myocardial perfusion grade, and TIMI thrombus
grade. The angiogram acquisition protocol required stored
ﬂuoroscopy of study drug administration to enable veriﬁcation
by the core laboratory that the guide catheter was selectively
engaged in the culprit artery when used to deliver study drug.
Angiographic methods are described in detail in Data S1.
The absolute percentage ST-segment resolution on ECGs
obtained 60 minutes after reperfusion compared with pre-
reperfusion was calculated. Troponin T area under the curve
was measured from blood samples obtained immediately
prereperfusion (0 hours) and then again 2 and 24 hours
later.
Cardiovascular Magnetic Resonance
CMR imaging was performed at 1.5 Tesla. The standard
operating procedure for CMR included: (1) microvascular
obstruction presence and extent (% LV mass) demonstrated
by late gadolinium enhancement images; (2) myocardial
hemorrhage presence and extent (% LV mass) demonstrated
by T2* mapped images; (3) infarct size (% LV mass)
demonstrated by late gadolinium enhancement images; and
(4) LV ejection fraction. Microvascular obstruction and
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myocardial hemorrhage were reported 2 to 7 days post-
STEMI; the other CMR parameters were reported at 2 to
7 days and 3 months post-STEMI. A detailed description of
the CMR acquisition and analysis techniques are in Data S1.
Coagulation
Coagulation and hemostasis parameters were measured in
peripheral blood samples taken prereperfusion, then 2 and
24 hours postreperfusion. The parameters included ﬁbrinogen
and plasminogen (measures of systemic ﬁbrinolysis), ﬁbrin D-
dimer (a measure of ﬁbrin lysis), tissue plasminogen activator
(a measure of endogenous ﬁbrinolytic system activation and
circulating alteplase), and prothrombin fragment F1+2 (a
measure of thrombin activation).
Clinical Outcomes
Clinical outcomes were prospectively collected between the
index event and 3-month follow-up. Major adverse cardiac
events was deﬁned as cardiovascular death, nonfatal myocar-
dial infarction, or unplanned hospitalization for heart failure.
All-cause death and heart failure hospitalization were also
reported. All events were adjudicated by a clinical event
committee who were independent of the trial and blinded to
the treatment allocation.
Sample Size
Sample-size calculation was based on data from the MR-MI
(Magnetic Resonance Imaging in Acute ST-Segment Elevation
Myocardial Infarction) cohort study12,15 in patients who
fulﬁlled the eligibility criteria for T-TIME. For a comparison
of IMR between 3 groups (placebo versus alteplase 10 mg
versus alteplase 20 mg), assuming a mean IMR of 33.9 and
an SD of 25.2, and assuming mean differences in IMR
between the 10 and 20 mg alteplase groups versus placebo
of 10 and 20, respectively, then 108 subjects (36/group)
were needed for 85% power and a signiﬁcance level of 0.05.
For a comparison of CFR between 3 groups (placebo versus
alteplase 10 mg versus alteplase 20 mg), assuming a mean
CFR of 1.65 and an SD of 0.8, and assuming mean differences
in CFR between the 10 and 20 mg alteplase groups versus
placebo were 0.4 and 0.8, respectively, then 69 subjects
(n=23/group) were needed with 85% power (a=0.05).
Statistical Analysis
Analyses were performed according to treatment received
(alteplase 10 mg, 20 mg, or placebo). Primary and secondary
outcomes were assessed using linear regression (contin-
uous outcomes), logistic regression (binary outcomes), or
proportional odds logistic regression (ordinal outcomes) to
make treatment effect estimates. In linear regression models,
logarithmic or square root transformations were used, where
necessary, to improve model residual distributions. We
performed post hoc analyses in prespeciﬁed subgroups. We
prespeciﬁed subgroups of interest according to patient char-
acteristics: (1) ischemic time (<2, 2–4, and ≥4 hours); (2) TIMI
thrombus grade immediately prestudy drug (≤2 and ≥3); and (3)
TIMI coronary ﬂow grade immediately prestudy drug (≤2, and
3). These subgroups were based on an a priori concern that
they were clinically relevant patient characteristics that could
potentially impact on associations of alteplase with IMR, CFR,
and RRR. Regression models were used to assess treatment
effects within prespeciﬁed subgroups through use of treat-
ment-by-subgroup interactions. Interaction test P values,
reported from regression models, included treatment group
as a 3-level categorical variable or as a 2-level categorical
variable (active versus placebo) and treatment modeled as a
linear trend across dose groups (0, 10, and 20 mg). Regression
analyses were adjusted for location of the myocardial infarc-
tion. All tests were 2-tailed and assessed at the 5% signiﬁcance
level. There was no imputation for missing values, and no
adjustments for multiple statistical comparisons were made.
Data were analyzed using R software (R Development Core
Team, Los Angeles, CA), according to a statistical analysis plan
that was ﬁnalized before data lock.
Results
Study Population Characteristics
Participants’ characteristics are shown in Tables 1 and 2. The
ﬂow of subjects through the study is summarized in Figure 2.
The sample size (n=144) represented 33% of the overall study
population, and their characteristics were broadly similar.
Mean age was 59.410.5 years, and 80% were male. Median
ischemic time was 2.5 hours (interquartile range [IQR], 2.0,
3.5), and 31 (22%) had an ischemic time <2 hours. The culprit
coronary artery was the left anterior descending in 38%
(n=54), circumﬂex in 17% (n=24), and right in 46% (n=66) of
patients.
At initial coronary angiography, TIMI ﬂow grade was ≤1 in
124 (88%) patients and 2 in 20 (12%) patients. The thrombus
grade at presentation was 5 (occluded vessel) in 116 (81%)
patients, 4 (thrombus dimension >2 vessel diameters) in 25
(17%) patients, and 3 (thrombus dimension >1/2 and <2
vessel diameters) in 3 (2%) patients. The residual thrombus
grade postreperfusion immediately before study drug delivery
was 4 in 46 (33%) patients, 3 in 62 (44%) patients, 2 in 21
(15%) patients, and 1 in 12 (9%) patients. All but one of the
patients received the study intervention according to the
protocol.
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Primary Physiology End Point
Median IMR for the entire population was 29.5 (IQR, 17.0,
55.0). Forty-eight percent (n=69) had an IMR >32 at the end
of the procedure, and 40% (n=57) had an IMR >40. On logistic
regression analysis, older age was the only baseline
characteristic that independently predicted an IMR >32
(mean age was 57.29.5 in those with IMR ≤32 and mean
age was 61.711.2 in those with IMR >32). Overall, IMR did
not differ between the alteplase groups (10, 20 mg) and
placebo (alteplase 10 mg: median 22.0 [IQR, 17.0, 42.0]
Table 1. Population Characteristics
All [n=144] Placebo [n=53] Alteplase 10 mg [n=41] Alteplase 20 mg [n=50]
Demographics
Age, y 59.410.5 56.811.3 61.29.4 60.610.3
Male 115 (80%) 45 (85%) 31 (76%) 39 (78%)
BMI, kg/m2 28.45.1 28.85.3 29.05.2 27.44.6
Ischemic time, h:mm median (IQR) 2:47 (2:03, 3:50) 2:40 (2:03, 3:52) 2:43 (1:53, 4:10) 2:54 (2:10, 3:36)
Medical history
Hypertension 41 (28%) 14 (26%) 11 (27%) 16 (32%)
Hypercholesterolemia 21 (15%) 11 (21%) 6 (15%) 4 (8%)
Diabetes mellitus* 16 (11%) 6 (11%) 6 (15%) 4 (8%)
Smoking
Current 68 (47%) 25 (47%) 17 (41%) 26 (52%)
Former 27 (19%) 13 (25%) 7 (17%) 7 (14%)
Never 49 (34%) 15 (28%) 17 (41%) 17 (34%)
Previous PCI 9 (6%) 3 (6%) 1 (2%) 5 (10%)
Previous MI 8 (6%) 2 (4%) 1 (2%) 5 (10%)
Angina 4 (3%) 2 (4%) 0 (0%) 2 (4%)
Stroke/TIA 3 (2%) 2 (4%) 0 (0%) 1 (2%)
Pre-existing maintenance medication
Aspirin 20 (14%) 8 (15%) 4 (10%) 8 (16%)
P2Y12 inhibitor
Clopidogrel 1 (1%) 1 (2%) 0 (0%) 0 (0%)
Ticagrelor/prasugrel 2 (1%) 0 (0%) 1 (2%) 1 (2%)
Statin 25 (17%) 13 (25%) 6 (15%) 6 (12%)
Βeta-blocker 14 (10%) 4 (8%) 4 (10%) 6 (12%)
ACEi or ARB 18 (12%) 7 (13%) 4 (10%) 7 (14%)
MRA 3 (2%) 1 (2%) 2 (5%) 0 (0%)
Hemodynamic measures and initial blood results on admission
Heart rate, bpm 73.015.1 74.416.1 71.513.0 72.715.8
Systolic BP, mm Hg 14026 14028 14123 13827
Diastolic BP, mm Hg 8215 8417 8213 8116
Creatinine, lmol/L† 7916 7916 8014 7917
eGFR, mL/min/1.73 m2† 9121 9422 8818 9222
Hemoglobin, g/L† 145.813.7 145.413.8 146.212.6 146.014.6
Platelet count, 109/L† 264.262.1 252.453.6 280.973.5 262.958.1
Data are meanSD, or n (%), unless otherwise stated. ACEi indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; BP, blood
pressure; eGFR, estimated glomerular ﬁltration rate; IQR, interquartile range; MI, myocardial infarction; MRA, mineralocorticoid receptor antagonist; PCI, percutaneous coronary
intervention; TIA, transient ischemic attack.
*Diabetes mellitus was deﬁned as a history of diet-controlled or treated diabetes mellitus.
†Missing data: creatinine, eGFR, hemoglobin, and platelets, 1 subject (alteplase 20 mg group).
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Table 2. Procedure Characteristics
All [n=144] Placebo [n=53]
Alteplase 10
mg [n=41]
Alteplase 20
mg [n=50]
Culprit artery
LAD 54 (38%) 19 (36%) 17 (41%) 18 (36%)
Circumflex 24 (17%) 9 (17%) 9 (22%) 6 (12%)
RCA 66 (46%) 25 (47%) 15 (37%) 26 (52%)
Culprit artery diameter, mm 3.2 0.4 3.20.5 3.20.5 3.20.4
Balloon angioplasty prestent 141 (98%) 51 (96%) 41 (100%) 49 (98%)
Initial angiography
TIMI coronary flow grade
0 114 (79%) 47 (89%) 34 (83%) 33 (66%)
1 14 (10%) 2 (4%) 3 (7%) 9 (18%)
2 16 (11%) 4 (8%) 4 (10%) 8 (16%)
3 0 (0%) 0 (0%) 0 (0%) 0 (0%)
TIMI thrombus grade
3 3 (2%) 0 (0%) 0 (0%) 3 (6%)
4 25 (17%) 6 (11%) 5 (12%) 14 (28%)
5 116 (81%) 47 (89%) 36 (88%) 33 (66%)
Immediately prestudy drug
TIMI coronary flow grade*
1 5 (4%) 2 (4%) 2 (5%) 1 (2%)
2 41 (29%) 14 (27%) 10 (24%) 17 (35%)
3 95 (67%) 35 (69%) 29 (71%) 31 (63%)
TIMI thrombus grade*
1 12 (9%) 5 (10%) 2 (5%) 5 (10%)
2 21 (15%) 10 (20%) 7 (17%) 4 (8%)
3 62 (44%) 21 (41%) 21 (51%) 20 (41%)
4 46 (33%) 15 (29%) 11 (27%) 20 (41%)
Study drug administration
Thrombectomy catheter 106 (74%) 39 (74%) 29 (71%) 38 (76%)
Guide catheter 35 (24%) 13 (25%) 11 (27%) 11 (22%)
Other 3 (2%) 1 (2%) 1 (2%) 1 (2%)
Poststudy drug
PCI with stent implant 144 (100%) 53 (100%) 41 (100%) 50 (100%)
Total stent length, mm 35.613.2 33.612.2 38.114.6 35.813.0
Poststent dilatation 133 (92%) 46 (87%) 41 (100%) 46 (92%)
Acute therapy following first medical contact†
Aspirin loading dose
300 mg 142 (99%) 53 (100%) 40 (98%) 49 (98%)
None 2 (1%) 0 (0%) 1 (2%) 1 (2%)
Additional antiplatelet medication
None 2 (1%) 0 (0%) 1 (2%) 1 (2%)
Clopidogrel 87 (60%) 27 (51%) 28 (68%) 32 (64%)
Continued
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versus placebo, 33.0 [17.0, 57.0]; relative difference, 0.79
[95% CI, 0.58, 1.07]; P=0.125; alteplase 20 mg: 37.0 [20.0–
57.8] versus placebo, 33.0; relative difference, 1.04 [95% CI,
0.78–1.38]; P=0.801; Table 3).
The intraclass correlation coefﬁcient (ICC) for IMR,
assessed from 30 consecutive patients, showed excellent
intrarater reliability (ICC, 0.998 [95% CI, 0.997, 0.999]) and
inter-rater reliability (ICC, 0.999 [95% CI, 0.998, 0.999]). The
mean difference between repeated IMR measurements from
12 patients was 6.33 (P=0.076).
Secondary Physiology End Points
Median CFR for the population was 1.4 (IQR, 1.1, 2.0). At the
end of the procedure, 115 (88%) patients had a CFR ≤2.0. The
median RRR for the entire population was 1.7 (IQR, 1.3, 2.3).
Overall, neither CFR nor RRR differed with alteplase versus
placebo (Table 3). The mean difference between repeated
CFR measurements from 9 patients was 0.07 (P=0.659). The
mean difference between repeated RRR measurements from
9 patients was 0.04 (P=0.860). The ICC for RRR, assessed
from 30 consecutive patients, showed excellent intrarater
reliability (ICC, 0.988 [95% CI, 0.974, 0.994]) and inter-rater
reliability (ICC, 0.988 [95% CI, 0.975, 0.994]).
Thermodilution waveforms or LV end-diastolic pressure did
not differ with alteplase versus placebo.
Angiographic, ECG, and Troponin Results
As in the main trial, there were no differences in ﬁnal TIMI
coronary ﬂow grade or TIMI frame count between treatment
groups (Table 4). TIMI myocardial perfusion grade was higher
in the alteplase 20 mg group compared with the placebo
group (odds ratio, 2.16 [95% CI, 1.04, 4.49]; P=0.039). There
was no difference in TIMI myocardial perfusion grade between
the alteplase 10 mg versus placebo group (odds ratio, 1.32
[95% CI, 0.60, 2.92]; P=0.496). Percent ST-segment resolution
60 minutes postreperfusion did not differ with alteplase
versus placebo (Table 4). Troponin T under the curve (0–
24 hours) did not differ with alteplase versus placebo
(Table 4).
Cardiovascular Magnetic Resonance Imaging
Results
CMR was performed in 140 patients (97%) from 2 to 7 days
after enrollment and in 135 patients (94%) at 3 months.
Overall, there was no difference in microvascular obstruction
or myocardial hemorrhage presence or extent, infarct size,
myocardial salvage, LV ejection fraction, or volumes with
alteplase versus placebo (Table S1).
Coagulation and Hematological Variables
There was an alteplase dose-related increase in systemic
concentrations of ﬁbrin D-dimer, reﬂecting ﬁbrinoylsis, and
prothrombin fragment F1+2, reﬂecting activation of the
clotting system, and a reduction in plasminogen, reﬂecting
the intended effect of alteplase (Table S2). Systemic concen-
trations of ﬁbrinogen and hemoglobin were similar between
treatment groups (Table S2), indicating that effects of
alteplase were localized to the heart.
Clinical Outcomes
Follow-up information was available for all patients at
3 months post-STEMI. Major adverse cardiac events occurred
in 20 patients by 3 months, of whom 7 received placebo, 7
Table 2. Continued
All [n=144] Placebo [n=53]
Alteplase 10
mg [n=41]
Alteplase 20
mg [n=50]
Ticagrelor 55 (38%) 26 (49%) 12 (29%) 17 (34%)
Prasugrel 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Unfractionated heparin,
U median (IQR)
11 500 (10 000, 15 000) 10 000 (10 000, 14 000) 12 000 (10 000, 15 000) 12 000 (10 000, 15 375)
Intravenous morphine 134 (93%) 48 (91%) 38 (93%) 48 (96%)
Inhaled oxygen 20 (14%) 8 (15%) 7 (17%) 5 (10%)
Glycoprotein IIb/IIIa
antagonist
8 (6%) 1 (2%) 5 (12%) 2 (4%)
Aspiration thrombectomy 23 (16%) 8 (15%) 8 (20%) 7 (14%)
Data are meanSD, or n (%), unless otherwise stated. IQR indicates interquartile range; LAD, left anterior descending artery; PCI, percutaneous coronary intervention; RCA, right coronary
artery; TIMI, Thrombolysis in Myocardial Infarction.
*Missing data: TIMI coronary ﬂow grade and TIMI thrombus grade immediately prestudy drug, 3 subjects (2 placebo, 1 alteplase 20 mg group).
†None of the patients received intravenous or intracoronary treatment with bivalirudin, metoprolol, nicorandil, or sodium nitroprusside.
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Figure 2. Diagram showing patient recruitment, randomization, and ﬂow through the T-TIME physiology substudy. CMR
indicates cardiovascular magnetic resonance; STEMI, ST-segment–elevation myocardial infarction; T-TIME, A Trial of Low-
Dose Adjunctive Alteplase During Primary PCI.
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received alteplase 10 mg, and 6 received alteplase 20 mg.
Three patients died during the 3-month follow-up period, of
whom 1 received alteplase 10 mg and 2 received alteplase
20 mg. There were 17 unplanned hospitalizations for heart
failure by 3 months (7 in the placebo group, 6 in the alteplase
10 mg group, and 4 in the alteplase 20 mg group).
Subgroup Analyses
Treatment effect estimates for IMR, CFR, and RRR measured
in the culprit coronary artery at the end of PCI in the
prespeciﬁed subgroups, based on postulated pathophysiolog-
ical mechanisms, are shown in Figure 3, Table 5, and Tables
S3 through S4.
Ischemic time
There was no interaction between ischemic time and alteplase
with IMR (Table 5). In patients with an ischemic time
<2 hours, median IMR was 45.0 (23.0, 53.2) with placebo,
29.0 (17.0, 36.0) with alteplase 10 mg, and 19.5 (15.0, 22.8)
with alteplase 20 mg. In patients with an ischemic time
≥4 hours, median IMR was 28.0 (19.0, 60.0) with placebo,
Table 3. Coronary Physiology End Points
Treatment Group Treatment Effect
All (n=144) Placebo (n=53)
Alteplase 10
mg (n=41)
Alteplase 20
mg (n=50)
20 mg vs Placebo 10 mg vs Placebo
10 or 20 mg
vs Placebo Trend With Dose
Estimate (95% CI)
P Value
Estimate (95% CI)
P Value
Estimate
(95% CI)
P Value
Estimate
(95% CI)
P Value
IMR* 29.5
(17.0, 55.0)
33.0
(17.0, 57.0)
22.0
(17.0, 42.0)
37.0
(20.0, 57.8)
1.04 (0.78, 1.38)
P=0.801
0.79 (0.58, 1.07)
P=0.125
0.92
(0.71, 1.18)
P=0.505
1.02
(0.88, 1.17)
P=0.824
IMR >40† 57 (40%) 24 (45%) 11 (27%) 22 (44%) 0.93 (0.42, 2.05)
P=0.864
0.42 (0.17, 1.02)
P=0.054
0.66
(0.33, 1.34)
P=0.251
0.96
(0.64, 1.43)
P=0.840
IMR >32† 69 (48%) 27 (51%) 15 (37%) 27 (54%) 1.12 (0.51, 2.44)
P=0.774
0.54 (0.23, 1.24)
P=0.147
0.81
(0.41, 1.60)
P=0.546
1.05
(0.71, 1.55)
P=0.794
CFR* 1.4 (1.1, 2.0) 1.3 (1.1, 1.8) 1.4
(1.1, 1.9)
1.4
(1.1, 2.0)
1.03 (0.88, 1.20)
P=0.732
1.01 (0.86, 1.19)
P=0.900
1.02
(0.89, 1.17)
P=0.777
1.01
(0.94, 1.09)
P=0.732
CFR ≤2† 115 (80%) 44 (83%) 31 (76%) 40 (80%) 1.23 (0.45, 3.36)
P=0.680
1.62 (0.59, 3.36)
P=0.680
1.40
(0.58, 3.36)
P=0.451
1.11
(0.68, 1.79)
P=0.681
RRR* 1.6 (1.3, 2.3) 1.6 (1.3, 2.2) 1.6
(1.4, 2.6)
1.8
(1.3, 2.4)
1.02 (0.87, 1.20)
P=0.795
1.04 (0.88, 1.23)
p=0.658
1.03
(0.90, 1.18)
=0.685
1.01
(0.93, 1.09)
0.790
Waveform‡
Unimodal
(narrow)
75 (52%) 26 (49%) 22 (54%) 27 (54%) 0.98 (0.46, 2.06)
P=0.956
1.00 (0.45, 2.20)
P=0.999
0.99
(0.52, 1.89)
P=0.972
0.99
(0.68, 1.44)
P=0.957Unimodal
(wide)
56 (39%) 25 (47%) 14 (34%) 17 (34%)
Bimodal 13 (9%) 2 (4%) 5 (12%) 6 (12%)
LVEDP,
mm Hg§
17.0
(12.0, 20.8)
16.5
(13.2, 19.0)
19.0
(13.2, 22.8)
15.0
(12.0, 18.8)
0.89 (0.75, 1.05)
P=0.172
1.05 (0.88, 1.25)
P=0.579
0.96
(0.83, 1.12)
P=0.609
0.94
(0.87, 1.03)
P=0.184
Data are median (IQR) or n (%). Between-group comparisons derived from linear, logistic, or ordinal logistic regression models, adjusted for location of MI (see footnotes). CFR indicates
coronary ﬂow reserve; IMR, index of microcirculatory resistance; IQR, interquartile range; LVEDP, left ventricular end-diastolic pressure; MI, myocardial infarction; RRR, resistive reserve
ratio.
*Data analyzed on logarithmic scale. Treatment effect estimates reported as relative differences between groups, with 95% CI and P value, from linear regression model adjusted for
location of MI.
†Treatment effect estimates reported as odds ratios between groups, with 95% CI and P value, from logistic regression model adjusted for location of MI.
‡Treatment effect estimates reported as odds ratio between groups, with 95% CI and P value, from ordinal logistic regression model adjusted for location of MI.
§Missing data: LVEDP, 18 subjects (7 placebo, 3 alteplase 10 mg, and 8 alteplase 20 mg group).
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19.0 (17.0, 34.0) with alteplase 10 mg, and 51.0 (26.8, 59.0)
with alteplase 20 mg.
Interactions were observed between ischemic time and
alteplase for CFR (P=0.013) and RRR (P=0.026; Figure 3;
Table 5). In patients with ischemic times<2 hours, median CFR
was higher with alteplase (placebo, 1.2 [1.1, 1.7]; alteplase
10 mg, 1.4 [1.0, 1.8]; alteplase 20 mg, 2.0 [1.8, 2.3]). RRR was
also higher with alteplase in patients with an ischemic time
<2 hours (placebo, 1.5 [1.3, 1.9]; alteplase 10 mg, 1.6 [1.1,
2.2]; alteplase 20 mg, 2.2 [2.0, 2.6]). In patients with an
ischemic time ≥4 hours, RRR was 2.0 (1.4, 2.7) with placebo,
2.3 (1.6, 2.8) with alteplase 10 mg, and 1.4 (1.0, 2.5) with
alteplase 20 mg. In those with an ischemic time ≥4 hours, CFR
was 1.7 (1.4, 2.0) with placebo, 1.8 (1.3, 2.6) with alteplase
10 mg, and 1.2 (1.0, 1.6) with alteplase 20 mg.
An interaction occurred between ischemic time and
alteplase for amount of microvascular obstruction
(P=0.022). In patients with an ischemic time ≥4 hours,
alteplase increased the mean extent of microvascular
obstruction: placebo (0.89  1.65%), alteplase 10 mg (2.77
 4.54%), and alteplase 20 mg (5.97  6.58%). In those
with an ischemic time <2 hours, mean amount of microvas-
cular obstruction was: 2.06  3.93% with placebo, 2.22 
3.98% with alteplase 10 mg, and 0.00  0.00% with alteplase
20 mg.
TIMI ﬂow and thrombus grades prestudy drug
There was no interaction between treatment group and
IMR, CFR, or RRR in the following subgroups: (1) TIMI
coronary ﬂow grade immediately prestudy drug
Table 4. ECG, Angiographic, and Troponin End Points
Treatment Group Treatment Effect
All (n=144)
Placebo
(n=53)
Alteplase Alteplase 20 mg vs Placebo
10 mg vs
Placebo
10 or 20 mg
vs Placebo
Trend With
Dose
10 mg (n=41)
20 mg
(n=50)
Estimate
(95% CI)
P Value
Estimate
(95% CI)
P Value
Estimate
(95% CI)
P Value
Estimate
(95% CI)
P Value
Absolute %
ST-segment
resolution
60 min*,†
46.6 (40.9) 45.1 (37.8) 45.7 (43.8) 48.8 (42.4) 4.15
(11.71, 20.02)
P=0.608
1.32
(15.53, 18.16)
P=0.878
2.89
(11.04,
16.83)
P=0.684
2.08
(5.83,
9.98)
P=0.607
TIMI flow grade
post-PCI‡
1.70
(0.51, 5.69)
P=0.391
1.43
(0.42, 4.84)
P=0.565
1.57
(0.57, 4.32)
P=0.387
1.31
(0.71, 2.41)
P=0.3831 3 (2%) 2 (4%) 0 1 (2%)
2 15 (10%) 6 (11%) 5 (12%) 4 (8%)
3 126 (88%) 45 (85%) 36 (88%) 45 (90%)
TIMI MPG
post-PCI‡
0 42 (29) 18 (34) 15 (37) 9 (18) 2.16
(1.04, 4.49)
P=0.039§
1.32
(0.60, 2.92)
P=0.496
1.75
(0.91, 3.37)
P=0.091
1.47
(1.02, 2.21)
P=0.039§
1 3 (2) 3 (6) 0 0
2 60 (42) 19 (36) 15 (37) 26 (52)
3 39 (27) 13 (25) 11 (27) 15 (30)
TFC post-PCI,
median (IQR)k
18.0
(14.0, 26.0)
18.0
(14.0, 26.0)
16.5
(14.0, 22.4)
22.0
(14.0, 24.5)
1.03
(0.84, 1.27)
P=0.774
0.89
(0.72, 1.11)
P=0.311
0.97
(0.80, 1.16)
P=0.713
1.01
(0.91, 1.13)
P=0.789
Troponin T AUC
0 to 24 h
(mg/L)‡,k
125.6
(143.2)
115.6
(139.5)
130.8
(142.4)
131.7
(150.5)
1.39
(0.83, 2.34)
P=0.213
1.56
(0.91, 2.67)
P=0.110
1.46
(0.93, 2.30)
P=0.098
1.18
(0.91, 1.53)
P=0.206
Data are meanSD, or n (%), unless otherwise stated. Between-group comparisons derived from linear, logistic, or ordinal logistic regression models, adjusted for location of MI (see
footnotes). AUC indicates area under the curve; IQR, interquartile range; MI, myocardial infarction; MPG, myocardial perfusion grade; PCI, percutaneous coronary intervention; TFC, TIMI
frame count; TIMI, Thrombolysis in Myocardial Infarction.
*Treatment effect estimates reported as mean differences between groups, with 95% CI and P value, from linear regression model adjusted for MI location.
†Missing data: ST-segment resolution 60 min, 3 subjects (2 placebo, 1 alteplase 10 mg group). Troponin T AUC, 21 subjects (8 placebo, 5 alteplase 10 mg, and 8 alteplase 20 mg group).
‡Treatment effect estimates reported as odds ratio between groups, with 95% CI and P value, from a proportional odds logistic regression model, adjusting for MI location.
kData analyzed on a logarithmic scale. Treatment effect estimates reported as relative difference between groups, with 95% CI and P value, from linear regression model adjusted for MI
location.
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dichotomized by ≤2 or 3; (2) TIMI thrombus grade
immediately prestudy drug dichotomized by ≤2 or ≥3
(Figure 3 and Tables S3 and S4).
Discussion
The main ﬁnding is that overall microvascular function,
assessed by IMR, CFR, and RRR, did not differ between
alteplase and placebo groups.
The lack of an overall treatment effect on microvascular
function in the culprit artery contrasts with the ﬁndings of Sezer
et al.27 In their proof-of-concept study, low-dose intracoronary
thrombolysis (streptokinase, 250 kU; n=51) was infused over
3 minutes through a guide catheter at the end of primary PCI
and, when compared with standard care (n=44), resulted in a
signiﬁcant increase in CFR and decrease in IMR (CFR, 2.5 versus
1.7; P<0.001; IMR, 20.2 versus 34.2; P<0.001).27
There are important differences between our study and
that of Sezer et al.27 First, the study by Sezer et al27 was not
Figure 3. Forest plots showing treatment effect estimates and interaction P values for IMR (index of microcirculatory resistance), CFR
(coronary ﬂow reserve), and RRR (resistive reserve ratio) in subgroups for ischemic time and TIMI (Thrombolysis in Myocardial Infarction)
coronary ﬂow grade and thrombus grade immediately before study drug delivery.
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double blinded, whereas our study was. Second, streptoki-
nase is not ﬁbrin speciﬁc, whereas alteplase is. Third, all of
the patients in Sezer et al’s study27 received a bolus of
tiroﬁban glycoprotein IIbIIIa inhibitor therapy at the start of
the procedure followed by tiroﬁban infusion for 12 hours,
whereas only 6% of patients in our study received a
glycoprotein IIbIIIa inhibitor, in line with current practice
guideline recommendations.28 Fourth, streptokinase was
delivered poststent when 89% of the cohort had TIMI 3
coronary ﬂow, whereas we administered alteplase prestent. In
our study, 46 patients (32%) had TIMI coronary ﬂow ≤2
immediately prestudy drug, which may have limited alteplase
reaching the downstream microcirculation, and prothrombotic
effects of ﬁbrinolytics might be enhanced in conditions of
slow ﬂow.29,30 Fifth, we measured coronary physiology
immediately after the primary PCI procedure, whereas Sezer
et al27 measured IMR and CFR 48 hours after primary PCI,
when IMR and CFR may have undergone partial recovery.31–33
In exploratory prespeciﬁed subgroup analyses, which were
intended to provide mechanistic insights and should be
interpreted as hypothesis generating, interactions were
observed between ischemic time and alteplase with CFR
and RRR, but not IMR. The improvement in microvascular
vasodilator function with alteplase, as reﬂected by higher CFR
and RRR, in patients with ischemic time <2 hours may be
explained by those patients presenting with a brief ischemic
time having intact microcirculation, which was modiﬁable by
therapy, whereas those with a longer ischemic time may have
had irreversible microvascular injury. While these observa-
tions could be attributed to type 1 statistical error, our
ﬁndings are supported by consistent effects of ischemic time
on extent of microvascular obstruction, for which the P value
for interaction was signiﬁcant.
In our study, alteplase was associated with more microvas-
cular obstruction in patients with an ischemic time ≥4 hours.
The ﬁndings suggest the possibility of alteplase having a
detrimental effect on myocardial reperfusion in patients with
longer ischemic time. The mechanism may involve alteplase
promoting myocardial hemorrhage in circumstances of pro-
longed ischemia, characterized by capillary degradation34 and
myocyte necrosis. An increase in extravasation of blood into
the interstitial space of the infarct core results in external
compression of capillaries, with an associated increase in
microvascular resistance. This leads to more microvascular
obstruction and potentiates the progression of myocardial
hemorrhage. The ﬁndings support the rationale to limit
eligibility to a short ischemic time (eg, <4 hours).
A plausible explanation for the lack of interaction between
ischemic time and alteplase with IMR could be because IMR
measures microvascular resistance during maximal hyperemia,
which might be less modiﬁable by intracoronary alteplase than
microvascular vasodilator function (measured by RRR and CFR).T
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Two other ongoing trials of low-dose intracoronary ﬁbri-
nolysis are using IMR as an eligibility criterion and to measure
acute microvascular function after intervention. The
RESTORE-MI (Restoring Microcirculatory Perfusion in STEMI)
trial (ACTRN12618000778280) will randomize STEMI patients
with IMR >32 (n=800) to intracoronary tenecteplase (one-
third of weight-based systemic dose) or placebo, in a double-
blind design, and those with IMR ≤32 will continue in a
followup registry. Recently, a pilot trial in 36 patients with
acute STEMI with symptoms ≤ 6 hours and TIMI 0/1 ﬂow in
the culprit artery demonstrated adjunctive low-dose (4 mg) of
intracoronary tenecteplase given twice (post-reperfusion and
at the end of PCI, 8 mg total) compared with placebo (saline)
as an adjunct to primary PCI was feasible and safe but did not
improve percent stenosis of the culprit lesion (primary
outcome).35 The smaller OPTIMAL (Optimal Coronary Flow
After PCI for Myocardial Infarction) trial (NCT02894138) will
randomize 80 STEMI patients with a poststenting IMR >30 to
intracoronary alteplase (20mg), or placebo, in an open-label
design. Both studies are including patients with ischemic
times up to 12 hours. However, our ﬁndings suggest that
therapeutic beneﬁt with alteplase might be restricted to
patients with a shorter ischemic time.
Limitations and Strengths
Because of the potential for type 1 error in the subgroup
analyses, these should be interpreted as exploratory. Although
we observed a higher TIMI myocardial perfusion grade post-PCI
in the alteplase 20 mg group compared with the placebo group,
this difference was not observed in the main trial,9 and the
signiﬁcant P value may have occurred because of chance (type
1 statistical error).
Strengths of our study include the randomized, double-
blind design, blinding of IMR, CFR, and RRR measurements to
minimize bias, and their excellent inter- and intrarater
reliability. Retention with CMR was high (94% at 3 months).
Conclusions
In acute STEMI with ischemic time ≤6 hours, there was,
overall, no difference in culprit artery microvascular function
(IMR, CFR, or RRR) at the end of PCI with alteplase versus
placebo. Interactions were observed between ischemic time
and alteplase on CFR, RRR, and microvascular obstruction,
implying therapeutic beneﬁt in patients presenting with a
shorter ischemic time and a detrimental effect in patients with
a longer ischemic time. Further research seems warranted.
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SUPPLEMENTAL MATERIAL 
 
 
 
Data S1. 
 
Eligibility Criteria 
Patients with a clinical diagnosis of acute ST-segment elevation myocardial infarction (STEMI) were 
eligible for randomization according to the following eligibility criteria: 
Inclusion 
• Acute MI (symptom onset ≤ 6 hours) with persistent ST-segment elevation or recent left bundle 
branch block 
• Coronary artery occlusion (TIMI [Thrombolysis in Myocardial Infarction] coronary flow grade 
0 or 1), or impaired coronary flow (TIMI coronary flow grade 2, slow but complete filling) in 
the presence of definite angiographic evidence of thrombus (TIMI grade 2 or more) 
• Proximal-mid culprit lesion location in a major coronary artery (i.e. the right, left anterior 
descending, intermediate, or circumflex artery) 
• Radial artery access 
• Successful coronary reperfusion (TIMI coronary flow grade ≥2) pre-stent achieved prior to 
randomization. 
• Informed consent, i.e. only patients who were sufficiently well to understand the information 
about the study, as described by the attending cardiologist, were eligible to participate.  
Exclusion 
• Normal flow in the culprit coronary artery at initial angiography (TIMI grade 3) 
• Functional coronary collateral supply (Rentrop grade 2/3) to the culprit artery 
• Previous infarction in the culprit artery (known or suspected clinically, e.g. wall motion 
abnormality revealed by echocardiography) 
• Cardiogenic shock (Killip Class IV) 
 
 
• Multivessel percutaneous coronary intervention (PCI) intended before the day 2-7 
cardiovascular magnetic resonance (CMR) scan 
• Estimated body weight <60 kg 
• Non-cardiac co-morbidity with expected survival <1 year 
• Contra-indication to contrast-enhance CMR imaging 
• Pacemaker, or implantable defibrillator 
• Known impaired renal function (estimated glomerular filtration rate <30ml/min) 
• Significant bleeding disorder either at present or within the past 6 months 
• Known hemorrhagic diathesis 
• Patient with current concomitant oral anticoagulation therapy (international normalized ratio 
>1.3), including apixaban, dabigatran and rivaroxaban 
• Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or spinal 
surgery) 
• Severe hypertension (blood pressure >180/110 mmHg) not controlled by medical therapy 
• Major surgery, biopsy of a parenchymal organ, or significant trauma within the past 3 months 
(this includes any trauma associated with the current acute MI) 
• Recent trauma to the head (<2 months) 
• Prolonged cardiopulmonary resuscitation (>2 minutes) within the past 2 weeks 
• Acute pericarditis and/ or subacute bacterial endocarditis 
• Acute pancreatitis 
• Severe hepatic dysfunction, including hepatic failure, cirrhosis, portal hypertension (esophageal 
varices) and active hepatitis 
• Active peptic ulceration 
• Arterial aneurysm and known arterial/ venous malformation 
• Neoplasm with increased bleeding risk 
 
 
• Any known history of hemorrhagic stroke, or stroke of unknown origin 
• Known history of ischemic stroke, or transient ischemic attack in the preceding 6 months 
• Dementia 
• Hypersensitivity to gentamicin, or natural rubber 
• Incapacity, or inability to provide informed consent 
• Previous randomization to this study, or participation in a study with an investigational drug, or 
medical device within 90 days prior to randomization 
• Women of child bearing potential (i.e. pre-menopausal), or breast feeding 
• Requirement for immunosuppressive therapy at any time during the preceding 3 months. This 
would include corticosteroids (but not inhaled or topical), drugs used following transplantation 
(e.g tacrolimus, cyclosporine), anti-metabolite therapies (e.g. mycophenolic acid, azathioprine, 
leflunomide and immunomodulators including biologics (e.g. adalimumab, or etanercept) and 
disease modifying anti-rheumatic drugs. This list is not exhaustive. 
• Active or prophylactic treatment with oral, or parenteral antibiotic, antifungal, or antiviral 
therapy, to prevent or treat infection 
• Any anti-cancer treatment (excluding surgery as this is covered above) at any time during the 
preceding 3 months, including chemotherapy, radiotherapy, and treatment with biologics, such 
as Vascular Endothelial Growth Factor Receptor (VEGFR) inhibitors (e.g. bevacizumab, 
pazopanib). This list is not exhaustive. 
• Any significant concurrent, or recent condition(s) not listed above that in the opinion of the 
treating clinician would pose an additional risk to the patient. 
Angiogram Acquisition & Analysis Methods 
Coronary angiograms were acquired during emergency care with cardiac catheter laboratory X-
ray and information technology equipment. The angiograms were analyzed using post-processing 
software (QAngio® XA Medis, Leiden, NL.) by experienced investigators who were blinded to 
 
 
treatment allocation. Catheter calibration was performed using the catheter calibration function on 
MEDIS QAngio. For each lesion, a view perpendicular to the long axis of the vessel was used in order 
to avoid foreshortening and overlap of branches. The single plane projection showing the best opacified 
and most severe lesion with minimal foreshortening and minimal branch overlap was selected.  
Feedback was provided to sites on the quality and completeness of the angiograms. 
TIMI Coronary Flow Grade 
The TIMI coronary flow grade was assessed using the following definitions1: 
 
TIMI coronary flow grade Definition 
0 No flow 
1 Minimal flow past obstruction 
2 Slow (but complete) filling and slow clearance 
3 Normal flow and clearance 
 
 
TIMI Myocardial Perfusion Grade 
TIMI myocardial perfusion grade provides a score for ground-glass appearance (‘blush’) of the 
contrast entering the microvasculature and contrast washout. TIMI myocardial perfusion grade was 
assessed according to the following definitions2: 
 
TIMI myocardial perfusion grade Definition 
0 Minimal or no myocardial blush in the distribution 
of the culprit artery. 
1 Myocardial blush is present in the distribution of 
the culprit artery. But there is incomplete 
 
 
clearance of dye between injections (with ~ 30 
seconds between injections). 
2 Myocardial blush is present in the distribution of 
the culprit artery. But there is slow contrast 
entry into the microvasculature and slow clearance 
of contrast. Specifically, blush is strongly persistent 
(i.e. either does not or only minimally diminishes in 
intensity) beyond 3 cardiac cycles after injection. 
3 Myocardial blush is present in the distribution of 
the culprit artery, with normal entry and exit 
of dye (mild/ moderate persistence of dye beyond 3 
cardiac cycles, but notably reduced after 3 cardiac 
cycles). Blush that is only mild intensity throughout 3 
cardiac cycles after injection (washout phase), but fades 
minimally is also classified as grade 3.  
 
TIMI Frame Count 
           The TIMI frame count represents the amount of time (in frames) for contrast dye to 
reach a standardized distal landmark2. If the culprit vessel was the left anterior descending 
artery the frame count was divided by 1.7 (correcting for longer vessel length). 
 
TIMI Coronary Thrombus Grade 
          Thrombus burden revealed during coronary angiography was classified according to 
the TIMI thrombus grade3: 
Thrombus grade Definition 
0 No angiographic characteristics of thrombus are present 
1 Possible thrombus is present, with reduced contrast density, 
haziness, irregular lesion contour, or a smooth convex 
‘meniscus’ at the site of total occlusion suggestive but not 
diagnostic of thrombus 
 
 
2 Definite thrombus, with greatest dimensions ≤ half the vessel 
diameter 
3 Definite thrombus but with greatest long axis dimension >1/2 
but <2 vessel diameters 
4 Definite thrombus, with the largest dimension ≥2 vessel 
diameters 
5 Total occlusion 
 
CMR Acquisition & Analysis 
CMR was performed using 1.5-T platforms (Siemens MAGNETOM Avanto, 
Erlangen, Germany and Philips Intera, Best, The Netherlands). The imaging protocol 
followed a standard operating procedure that included planning and localisers, T1-mapping, 
T2*-mapping, cine CMR with steady-state free precession (SSFP), and late gadolinium 
enhancement imaging 10 – 15 minutes after administration of contrast media4. The scan 
acquisitions were spatially co-registered and also included different slice orientations to 
enhance diagnostic confidence. 
The intravenous contrast agent used in this study was gadobutrol (Gadovist®, Bayer: 
1.5 mmol/ml solution for injection), which was administered in two doses. The first dose 
injection (0.05 mmol/kg) was given to initiate the first-pass of contrast. The second dose (0.1 
mmol/kg) was given immediately after the first-pass. Therefore, the total dose of gadobutrol 
was 0.15 mmol/kg.  
SSFP cine breath-hold sequences (with parallel imaging acceleration) were used. The 
heart was imaged in multiple parallel SAX planes 8-mm thick, separated by 2mm gaps, 
equating to approximately 10 slices and 30 cardiac phases. The CMR analyses were 
undertaken using Medis® Suite MR (Medis, Leiden, NL), by two trained investigators who 
 
 
were blinded to treatment allocation. P.McC undertook the primary analysis of the scans and 
related analyses were reviewed by C.B. (second reviewer).  
Late Enhancement  
Late microvascular obstruction (MVO) was imaged 10-15 minutes after intravenous 
Gadovist contrast administration, using in general a motion corrected T1-weighted phase-
sensitive inversion recovery radiofrequency pulse sequence. A full stack, aligned to T2* 
scans (or cines) and 3 long axis views (vertical long axis, horizontal long axis and 3 chamber 
view) were acquired. 
 MVO was defined as a dark zone on early gadolinium enhancement imaging 1, 3, 5 
and 7-minutes post-contrast injection that remained present within an area of late gadolinium 
enhancement at 15 minutes. The endocardial and epicardial borders were contoured. The 
myocardial mass (grams) of the dark zone was quantified by manual delineation and 
expressed as a percentage of total left ventricular (LV) mass. 
Infarct Definition & Size 
The presence of acute infarction was established based on abnormalities in cine wall 
motion, rest first-pass myocardial perfusion, and late gadolinium enhancement imaging in 
two imaging planes. The myocardial mass of late gadolinium (grams) was quantified using 
computer assisted planimetry and the territory of infarction was delineated using a 5 standard 
deviation method and expressed as a percentage of total LV mass. Typical late gadolinium 
enhancement and MVO imaging parameters with phase sensitive inversion recovery: matrix 
192 x 256 pixels; flip angle 25o; TE 3.36 ms; bandwidth 130 Hz/pixel; echo spacing 8.7ms 
and trigger pulse 2. The voxel size is 1.8 x 1.3 x 8 mm. Inversion times individually adjusted 
to optimize nulling of apparently normal myocardium (typical values, 200 to 300ms). 
Myocardial Edema 
 
 
The presence of myocardial oedema was established based on an area of increased 
signal intensity on the SSFP cine images (acquired two minutes after gadolinium contrast 
injection). The myocardial mass was calculated by manual delineation in end-diastole and 
end-systole. The values were averaged and expressed as a percentage of LV mass4. 
Myocardial Salvage 
Myocardial salvage was calculated by subtraction of percent infarct size from percent 
area-at risk, as reflected by the extent of oedema. The myocardial salvage index was 
calculated by dividing the myocardial salvage area by the initial area-at-risk. 
Myocardial Hemorrhage 
On the T2* parametric maps, a threshold of 20ms was applied. A region of reduced 
signal intensity within the infarcted area, with a T2* value of <20 ms5,6 was considered to 
confirm the presence of myocardial hemorrhage. The area was manually delineated and 
expressed as % LV mass.
 
 
 
Table S1. CMR endpoints. Data are mean  SD, or n (%), unless otherwise stated. Between-group comparisons derived from linear, logistic, or ordinal logistic regression 
models, adjusted for location of MI (see footnotes). 
 Treatment Group  Treatment Effect 
 All Placebo Alteplase 
10mg 
Alteplase 
20mg 
 20mg vs. placebo   10mg vs. placebo  10 or 20mg vs. placebo  Trend with dose 
 [n=144] [n=53] [n=41] [n=50]  Estimate (95% CI)  
p-value  
 Estimate (95% CI)  
p-value 
 Estimate (95% CI)  
p-value 
 Estimate (95% CI)  
p-value  
CMR 2 – 7 day             
Microvascular obstruction 
extent (% LV) *† ‡ 
2.5  4.5 2.0  3.1 2.5  4.2 2.9  5.7  0.08 (-0.43, 0.59)  
p=0.766 
 0.03 (-0.50, 0.56) 
p=0.908 
 0.06 (-0.50, 0.50) 
p=0.804 
 0.04 (-0.21, 0.29) 
p=0.766 
Microvascular obstruction 
presence * ‡ ‡ 
57 (41) 23 (45) 16 (39) 18 (38)  0.73 (0.33, 1.64)  
p=0.449 
 0.78 (0.34, 1.81) 
p=0.566 
 0.76 (0.38, 1.52) 
p=0.432 
 0.85 (0.57, 1.28) 
p=0.446 
Myocardial haemorrhage extent 
(% LV) * ‡‡‡ 
2.0  3.9 1.6  2.8 2.1  3.8 2.4  4.8  0.72 (-0.87, 2.31) 
 p=0.373 
 0.44 (-1.28, 2.16) 
p=0.619 
 0.60 (-0.81, 2.01) 
p=0.403 
 0.36 (-0.43, 1.15) 
p=0.372 
Myocardial hemorrhage 
presence * ‡ ‡ 
56 (41) 22 (45) 16 (41) 18 (38)  0.73 (0.33, 1.66)  
p=0.458 
 0.85 (0.36, 2.00) 
p=0.713 
 0.79 (0.38, 1.60) 
p=0.506 
 0.86 (0.57, 1.29) 
p=0.458 
Acute Infarct size (% LV) * ‡‡‡ 24.1  12.7 23.3  12.9 26.6  12.5 23.1  12.8  -0.70 (-5.35, 3.94)  
p=0.767 
 2.57 (-2.29 7.42) 
p=0.300 
 0.80 (-3.27, 4.87) 
p=0.700 
 -0.33 (-2.66, 2.00) 
p=0.781 
LV ejection fraction (%) * ‡‡‡ 43.9   8.3 44.3  7.6 43.6  7.6 43.7  9.7  -0.32 (-3.48, 2.84)  
p=0.844 
 -0.25 (-3.55, 3.05) 
p=0.882 
 -0.29 (-3.04, 2.47) 
p=0.838 
 -0.16 (-1.74, 1.42) 
p=0.842 
LV end systolic volume (ml), * 
median (IQR) ‡ ‡‡ ‡ 
90.5 
(77.5, 108.3) 
90.4 
(80.9, 108.8) 
92.9 
(83.2, 106.8) 
89.9 
(66.1, 108.3) 
 0.94 (0.84, 1.06)  
p=0.306 
 1.00 (0.88, 1.12) 
p=0.946 
 0.97 (0.87, 1.07) 
p=0.503 
 0.97 (0.92, 1.03) 
p=0.308 
LV end diastolic volume (ml), * 
median (IQR) ‡ ‡‡ ‡ 
166.0 
(143.5, 188.4) 
168.7 
(151.3, 196.5) 
73.5 
(147.1, 187.9) 
157.9 
(131.6, 187.1) 
 0.94 (0.86, 1.03)  
p=0.189 
 0.99 (0.90, 1.09) 
p=0.850 
 0.96 (0.89, 1.04) 
p=0.360 
 0.97 (0.93, 1.01) 
p=0.190 
CMR 3 months             
Infarct size (% LV) * ‡‡‡ 17.0   11.5 17.0  11.9 17.7  11.0 16.5  11.7  -0.62 (-5.04, 3.80)  
p=0.782 
 0.45 (-4.16, 5.06) 
p=0.848 
 -0.13 (-4.00, 3.74) 
p=0.947 
 -0.31 (-2.52, 1.89) 
p=0.780 
 
 
Myocardial salvage index * ‡‡‡ 0.6  0.2 0.6  0.3 0.6  0.2 0.6  0.2  0.02 (-0.08, 0.12)  
p=0.707 
 0.02 (-0.08, 0.13) 
p=0.670 
 0.02 (-0.07, 0.11) 
p=0.642 
 0.01 (-0.04, 0.06) 
p=0.708 
LV ejection fraction * ‡‡‡ 49.1  8.4 49.5  8.4 49.0  6.5 48.9  9.8  -0.45 (-3.77, 2.88)  
p=0.793 
 -0.32 (-3.79, 3.14) 
p=0.855 
 -0.39 (-3.29, 2.51) 
p=0.792 
 -0.22 (-1.88, 1.43) 
p=0.792 
LV end systolic volume (ml), * 
median (IQR) ‡ ‡‡ ‡ 
81.1 
(65.7, 102.2) 
82.5 
(69.0, 99.8) 
81.8 
(70.1, 92.9) 
73.4 
(61.6, 109.6) 
 0.95 (0.83, 1.09)  
p=0.484 
 0.97 (0.84, 1.12) 
p=0.687 
 0.96 (0.85, 1.08) 
p=0.513 
 0.98 (0.91, 1.05) 
p=0.482 
LV end diastolic volume (ml), * 
median (IQR) ‡ ‡‡ ‡ 
162.8 
(141.6, 186.2) 
165.6 
(149.2, 188.9) 
164.6 
(147.0, 176.9) 
151.6 
(132.7, 183.3) 
 0.93 (0.85, 1.02)  
p=0.140 
 0.96 (0.87, 1.06) 
p=0.403 
 0.95 (0.87, 1.02) 
p=0.170 
 0.97 (0.92, 1.01) 
p=0.138 
Change in LV end diastolic 
volume at 3 months from 2-7 
days (ml), * median (IQR) ‡ ‡‡ ‡ 
-3.5 
(-13.5, 10.0) 
1.7 
(-12.0, 14.6) 
-4.7 
(-13.1, 6.2) 
-4.3 
(-16.4, 12.8) 
 -7.80 (-17.82, 2.21)  
p=0.127 
 -9.53 (-19.98, 0.92) 
p=0.074 
 -8.60 (-17.34, 0.15) 
p=0.054 
 -3.92 (-8.93, 1.10) 
p=0.126 
 ‡  Data analyzed on square root scale. Treatment effect estimates reported as mean differences in square root of MVO extent between groups, 
with 95% confidence interval and p-value, from linear regression model adjusted for MI location. 
‡ ‡ Treatment effect estimates reported as odds ratios between groups, with 95% confidence interval and p-value, from a logistic regression 
model, adjusting for MI location. 
‡ ‡ ‡ Treatment effect estimates reported as mean differences between groups, with 95% confidence interval and p-value, from linear regression 
model adjusted for MI location. 
‡ ‡ ‡ ‡ Treatment effect estimates reported as relative differences between groups, on a log-transformed scale, with 95% confidence interval and p-
value, from linear regression model adjusted for MI location. 
*Missing data: Change in LV end diastolic volume at 3 months from 2 – 7 days, 9 subjects (5 placebo, 1 alteplase 10mg, 3 alteplase 20mg). 
Infarct size, LV ejection fraction, 2 – 7 days post-PCI, 4 subjects (2 placebo, 2 alteplase 20mg group). LV ejection fraction, 3 months post-PCI, 
9 subjects (5 placebo, 1 alteplase 10mg, 3 alteplase 20mg group). Infarct size/ myocardial salvage index 3 months post-PCI, 11 subjects (7 
placebo, 1 alteplase 10mg, 3 alteplase 20mg group). LV end diastolic/ systolic volume 2 – 7 days post-PCI, 4 subjects (2 placebo, 2 alteplase 
20mg). LV end diastolic/ systolic volume 3 months post-PCI, 9 subjects (5 placebo, 1 alteplase 10mg, 3 alteplase 20mg). Microvascular 
obstruction extent/ presence, infarct size, LV ejection fraction, 4 subjects (2 placebo, 2 alteplase 20mg group). Myocardial hemorrhage extent 13 
subjects (6 placebo, 5 alteplase 10mg, 2 alteplase 20mg group). Myocardial hemorrhage extent, 13 subjects (6 placebo, 5 alteplase 10mg, 2 
alteplase 20mg). Myocardial hemorrhage presence/ absence, 8 subjects (8 placebo, 2 alteplase 10mg, 2 alteplase 20mg group †Microvascular 
obstruction was presented as mean  SD, because the high proportion of patients with a 0 value for microvascular obstruction amount resulted in 
median values for microvascular obstruction of 0 in each group. 
 
 
 
 
    Table S2. Coagulation and hematological variables. Data are mean  SD, or n (%), unless otherwise stated. Between-group comparisons derived from 
linear, logistic, or ordinal logistic regression models, adjusted for location of MI (see footnotes). 
 Treatment Group  Treatment effect 
 All Placebo Alteplase 10mg Alteplase 20mg  20mg vs. placebo  10mg vs. placebo  10 or 20mg vs. placebo  Trend with dose 
 [n=144] [n=53] [n=41] [n=50]  Estimate (95% CI)  
p-value  
 Estimate (95% CI)  
p-value 
 Estimate (95% CI)  
p-value 
 Estimate (95% CI)  
p-value  
Hemoglobin (g/L) at 24 hrs * ‡ 
 
142.1  12.5 143.5  10.8 141.1  12.1 141.6  14.5  -1.98 (-6.90, 2.94)  
p=0.431 
 -2.61 (-7.72, 2.49)  
p=0.316 
 -2.28 (-6.55, 2.00) 
p=0.297 
 -1.00 (-3.46, 1.45) 
p=0.423 
 
Activated clotting time (s) at 2 
hrs * ‡‡ 
288.9  92.0 302.3  103.3 298.3  83.1 266.9  83.5  0.89 (0.80, 1.00)  
p=0.046 
 1.00 (0.89, 1.13)  
p=0.940 
 0.94 (0.85, 1.04) 
p=0.230 
 0.94 (0.89, 1.00) 
p=0.048 
 
Fibrinogen 2 hrs post-PCI * ‡‡‡ 3.3  0.9 3.4  1.0 3.3  1.1 3.3  0.6  1.00 (0.90, 1.11)  
p=0.960 
 0.98 (0.88, 1.09) 
p=0.703 
 0.99 (0.90, 1.08) 
p=0.809 
 1.00 (0.95, 1.05) 
p=0.954 
Plasminogen (U/dL) 2 hrs post-
PCI *‡ 
89.4  14.7 95.3  14.3 90.1  12.4 82.5  14.2  -12.9 (-18.4, -7.30)  
p<0.001 
 -5.20 (-11.00, 0.60)  
p=0.076 
 -9.40 (-14.30, -4.40) 
p=0.0002 
 -6.40 (-9.20, -3.70) 
p<0.001 
 
Change in plasminogen (U/dL) 2 
hrs post-PCI compared to 
baseline *‡ 
-5.3  9.0 -0.1  7.8 -4.7  8.0 -11.3  7.3  -11.30 (-14.40, -8.10)  
p<0.001 
 -4.60 (-7.80, -1.30)  
p=0.006 
 -8.20 (-11.10, -5.30) 
p<0.001 
 -5.60 (-7.20, -4.10) 
p<0.001 
 
D-dimers 2 hrs post-PCI * ‡‡‡ 394.1  543.3 142.4  127.3 536.2  695.8 541.7  580.8  3.49 (2.50, 4.87)  
p<0.001 
 3.23 (2.28, 4.58)  
p<0.001 
 3.37 (2.52, 4.50) 
p<0.001 
 1.88 (1.58, 2.23) 
p<0.001 
 
tPA 2 hrs post-PCI (ng/ml) * ‡‡‡ 23.2  54.4 17.4  35.6 15.4  8.0 36.1  84.1  1.55 (1.22, 1.97) 
p=0.0004 
 1.16 (0.90, 1.49) 
 p=0.244 
 1.36 (1.10, 1.68) 
p=0.005 
 1.24 (1.10, 1.40) 
p=0.0004 
 
 
 
Ratio of tPA 2 hrs post-PCI 
compared to baseline * ‡‡‡ 
1.58  1.34 1.16  0.27 1.43  0.59 2.17  2.09  1.58 (1.36, 1.84)  
p<0.001 
 1.20 (1.03, 1.41)  
p=0.022 
 1.39 (1.21, 1.60) 
p<0.001 
 1.26 (1.16, 1.35) 
p<0.001 
 
Prothrombin fragment F1+2 
(pmol/L) 2 hrs post-PCI, median 
(IQR) * ‡‡‡ 
178.8  
(133.1, 244.2) 
152.0  
(118.6, 211.4) 
183.0  
(141.9, 291.9) 
187.3  
(150.5, 244.9) 
 1.24 (1.00, 1.52)  
p=0.048 
 1.27 (1.02, 1.58)  
p=0.034 
 1.25 (1.04, 1.50) 
p=0.017 
 1.11 (1.00, 1.24) 
p=0.046 
 
 
‡ Treatment effect estimates reported as mean differences between groups, with 95% confidence interval and p-value, from linear regression 
model adjusted for MI location. 
‡ ‡ Treatment effect estimates reported as relative differences between groups, with 95% confidence interval and p-value, from linear regression 
model adjusted for MI location. 
‡ ‡ ‡  Data analyzed on logarithmic scale. Treatment effect estimates reported as relative difference between groups, with 95% confidence interval 
and p-value, from linear regression model adjusted for MI location. 
* Missing data: Hemoglobin at 24 hours, 6 subjects (3 placebo, 3 alteplase 20mg group). Activated clotting time, 6 subjects (5 from placebo, 1 
from alteplase 10mg group). tPA/ fibrinogen/ d-dimer 2 hours post-PCI, 10 subjects (4 placebo, 2 alteplase 10mg, 4 alteplase 20mg group). tPA 
ratio 2 hours post-PCI compared to baseline, 15 subjects (6 placebo, 3 alteplase 10mg, 6 alteplase 20mg group). Prothrombin fragment F1+2 two 
hours post-PCI, 15 subjects (6 placebo, 3 alteplase 10mg, 4 alteplase 20mg group). Plasminogen 2 hours post-PCI, 10 subjects (4 placebo, 2 
alteplase 10mg. 4 alteplase 20mg group). Change in plasminogen 2 hours post-PCI compared to baseline 15 subjects (6 placebo, 3 alteplase 
10mg, 6 alteplase 20mg).
 
 
 
Table S3. IMR, CFR and RRR in sub-groups of TIMI coronary flow grade immediately before study drug delivery. Data are median (IQR). Data analyzed on 
logarithmic scale. Treatment effect estimates reported as relative differences, derived from linear regression models, adjusted for location of MI. 
TIMI flow grade 
pre-study drug  
Placebo Alteplase 10mg Alteplase 20mg  Treatment Effect Interaction 
p-value 
(treatment 
as 3-level 
categorical 
variable) 
Treatment Effect Interaction 
p-value 
(treatment 
as 2-level 
categorical 
variable) 
Treatment Effect Interaction 
p-value 
(treatment 
as per 10mg 
increase in 
dose) 
[n=53] [n=41] [n=50]  20mg vs. placebo  10mg vs. placebo 10 or 20mg vs. 
 placebo 
Trend with dose 
IMR ≤ 2 [n] 
              
    3 [n] 
40.5 (29.5, 61.0)  
[16] 
28.0 (16.0, 50.5)  
[35] 
50.5 (26.5, 69.8)  
[12] 
19.0 (16.0, 30.0)  
[29] 
50.5 (25.8, 77.0)  
[18] 
30.0 (17.5, 46.5)  
[31] 
 1.05 (0.65, 1.71)  
p=0.835 
1.02 (0.72, 1.45)  
p=0.896 
 1.03 (0.61, 1.77)  
p=0.903 
0.72 (0.51, 1.02)  
p=0.835 
0.481 1.05 (0.68, 1.62) 
p=0.834 
0.86 (0.64, 1.16) 
p=0.335 
0.473 1.03 (0.81, 1.31) 
p=0.828 
1.00 (0.84, 1.20) 
p=0.959 
0.883 
CFR ≤ 2 [n] 
              
   3 [n] 
1.6 (1.2, 2.1)  
[16] 
1.3 (1.1, 1.8)  
[35] 
1.4 (1.2, 1.8)  
[12] 
1.4 (1.1, 2.1)  
[29] 
1.3 (1.0, 2.0)  
[18] 
1.6 (1.3, 2.0)  
[31] 
 0.84 (0.64, 1.10)  
p=0.198 
1.16 (0.95, 1.41) 
p=0.139 
 0.88 (0.65, 1.18)  
p=0.396 
1.07 (0.88, 1.31)  
p=0.472 
0.159 0.85 (0.67, 1.09) 
p=0.201 
1.12 (0.95, 1.32) 
p=0.192 
0.074 0.92 (0.80, 1.05) 
p=0.198 
1.08 (0.98, 1.18) 
p=0.136 
0.056 
RRR ≤ 2 [n] 
 
     3 [n] 
2.0 (1.4, 2.3)  
[16] 
1.6 (1.3, 2.2)  
[35] 
1.9 (1.4, 2.3)  
[12] 
1.6 (1.4 2.6)  
[29] 
1.5 (1.1, 2.2)  
[18] 
2.0 (1.5, 2.4)  
[31] 
 0.82 (0.62, 1.08)  
p=0.158 
1.16 (0.95, 1.41)  
p=0.154 
 0.90 (0.66, 1.23)  
p=0.502 
1.10 (0.90, 1.35)  
p=0.341 
0.140 0.85 (0.66, 1.09) 
p=0.203 
1.13 (0.95, 1.34) 
p=0.160 
 
0.065 0.90 (0.79, 1.04) 
p=0.155 
1.08 (0.97, 1.19) 
p=0.148 
0.046 
 
 
 
 
 
 
 
 
 
 
Table S4. IMR, CFR and RRR in sub-groups of TIMI thrombus grade immediately before study drug delivery. Data are median (IQR). Data analyzed on 
logarithmic scale. Treatment effect estimates reported as relative differences, derived from linear regression models, adjusted for location of MI. 
Thrombus grade 
pre-study drug  
 
 
Placebo Alteplase 10mg Alteplase 20mg  Treatment Effect Interaction 
p-value 
(treatment 
as 3-level 
categorical 
variable) 
Treatment Effect Interaction 
p-value 
(treatment 
as 2-level 
categorical 
variable) 
Treatment Effect Interaction 
p-value 
(treatment 
as per 10mg 
increase in 
dose) 
[n=53] [n=41] [n=50]  20mg vs. placebo  10mg vs. placebo 10 or 20mg vs. 
 placebo 
Trend with dose 
IMR ≤ 2 [n] 
         ≥ 3 [n] 
 
21.0 (15.0, 49.0)  
[15] 
39.5 (21.8, 57.2)  
[36] 
39.0 (17/0, 44.0)  
[9] 
20.0 (16.0, 33.2)  
[32] 
37.0 (20.0, 45.0) 
 [9] 
38.5 (19.8, 58.2)  
[40] 
 1.33 (0.72, 2.44)  
p=0.363 
0.97 (0.70, 1.36)  
p=0.865 
 1.24 (0.67, 2.29)  
p=0.498 
0.69 (0.48, 0.98)  
p=0.036 
0.260 1.28 (0.77, 2.13) 
p=0.348 
0.83 (0.62, 1.12) 
p=0.231 
0.158 1.16 (0.85, 1.57) 
p=0.353 
0.99 (0.84, 1.17) 
p=0.231 
0.158 
CFR ≤ 2 [n] 
         ≥ 3 [n] 
 
1.3 (1.1, 2.1)  
[15] 
1.3 (1.1, 1.8)  
[36] 
1.1 (1.1, 1.6)  
[9] 
1.4 (1.3, 2.1)  
[32] 
1.8 (1.5, 2.0)  
[9] 
1.4 (1.2, 2.0)  
[40] 
 1.06 (0.76, 1.48)  
p=0.737 
1.03 (0.86, 1.23)  
p=0.753 
 0.86 (0.62, 1.21)  
p=0.393 
1.05 (0.87, 1.28)  
p=0.595 
0.506 0.96 (0.73, 1.26) 
p=0.759 
1.04 (0.89, 1.22) 
p=0.637 
0.616 1.02 (0.86, 1.20) 
p=0.843) 
1.01 (0.93, 1.11) 
p=0.765 
0.976 
RRR ≤ 2 [n] 
          ≥ 3 [n] 
 
1.6 (1.3, 2.5)  
[15] 
1.6 (1.4, 2.2)  
[36] 
1.4 (1.2, 2.0)  
[9] 
1.8 (1.5, 2.7)  
[32] 
2.0 (1.7, 2.0)  
[9] 
1.7 (1.3, 2.4)  
[40] 
 1.05 (0.75, 1.48)  
p=0.767 
1.02 (0.85 1.23)  
p=0.840 
 0.87 (0.61, 1.23)  
p=0.424 
1.09 (0.89, 1.33)  
p=0.412 
0.440 0.96 (0.72, 1.27) 
p=0.768 
1.05 (0.89, 1.24) 
p=0.580 
0.595 1.01(0.86, 1.20) 
p=0.865 
1.01 (0.92, 1.11) 
P=0.863 
0.948 
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